SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $362,202,120 |
| Positions | 9 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ALUMIS INC. | ALMS | COM | $165,941,439 | 5,896,995 |
| CG Oncology, Inc. | CGON | COM | $76,666,503 | 1,079,050 |
| Disc Medicine, Inc. | IRON | COM | $27,359,407 | 374,069 |
| Hims & Hers Health, Inc. | HIMS | COM CL A | $25,591,695 | 738,151 |
| Pharvaris N.V. | PHVS | COM | $22,966,030 | 664,142 |
| Eikon Therapeutics, Inc. | EIKN | COM | $17,212,728 | 1,318,983 |
| Odyssey Therapeutics, Inc. | ODTX | COM | $13,342,195 | 713,105 |
| Lyell Immunopharma, Inc. | LYEL | COM | $6,693,223 | 476,386 |
| Nurix Therapeutics, Inc. | NRIX | COM | $6,428,900 | 265,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.